Market Spotlight: Basal Cell Carcinoma
Market Spotlight: Basal Cell Carcinoma
This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, epidemiology, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- The approved drugs in the basal cell carcinoma space target the immune system, thymidylate synthase, reactive oxygen species/free radicals, and Hedgehog signaling pathway. The majority of these therapies are administered via the topical route, with the remainder being oral formulations.
- The greatest proportion of industry-sponsored drugs in active clinical development for basal cell carcinoma are in Phase II, with two drugs in Phase III.
- Therapies in the pipeline for basal cell carcinoma focus on a wide variety of targets. These drugs are administered via the topical, oral, intravenous, and intratumoral routes.
- High-impact upcoming events for drugs in the basal cell carcinoma space comprise topline Phase II trial results for Libtayo and topline Phase III trial results for Ameluz.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.6%, and the average probability a drug advances from Phase III is 41%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- There have been five licensing and asset acquisition deals involving basal cell carcinoma drugs during 2014–19. The $175m agreement between Sun Pharmaceutical and Novartis made in December 2016 for the acquisition of Novartis’s branded oncology product Odomzo by Sun Pharmaceutical was the largest deal.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for basal cell carcinoma have been in the early and mid-phases of development, with 80% of trials in Phase I–II, and only 20% in Phase III–IV.
- The US has a substantial lead in the number of basal cell carcinoma clinical trials globally, while the UK leads the major EU markets.
- Clinical trial activity in the basal cell carcinoma space is dominated by completed trials. Roche has the highest number of completed clinical trials for basal cell carcinoma, with 17 trials.
- Roche leads industry sponsors with the highest overall number of clinical trials for basal cell carcinoma, followed by Novartis.
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 Electrodesiccation and curettage (ED&C)
8 Mohs micrographic surgery
8 Excisional surgery
8 Radiation therapy
9 Photodynamic therapy (PDT)
9 Laser surgery
9 Pharmacological therapies
11 Recent incidence studies
12 MARKETED DRUGS
14 PIPELINE DRUGS
19 RECENT EVENTS AND ANALYST OPINION
19 SRT-100 for Basal Cell Carcinoma (April 23, 2019)
20 Erivedge for Basal Cell Carcinoma (March 25, 2019)
22 KEY UPCOMING EVENTS
23 PROBABILITY OF SUCCESS
24 LICENSING AND ASSET ACQUISITION DEALS
25 PARENT PATENTS
26 CLINICAL TRIAL LANDSCAPE
27 Sponsors by status
28 Sponsors by phase
29 Recent events
30 Prescription information
LIST OF FIGURES
14 Figure 1: Overview of pipeline drugs for basal cell carcinoma in the US
14 Figure 2: Pipeline drugs for basal cell carcinoma, by company
15 Figure 3: Pipeline drugs for basal cell carcinoma, by drug type
15 Figure 4: Pipeline drugs for basal cell carcinoma, by classification
22 Figure 5: Key upcoming events in basal cell carcinoma
23 Figure 6: Probability of success in the basal cell carcinoma pipeline
24 Figure 7: Licensing and asset acquisition deals in basal cell carcinoma, 2014–19
25 Figure 8: Parent patents in basal cell carcinoma
26 Figure 9: Clinical trials in basal cell carcinoma
26 Figure 10: Top 10 drugs for clinical trials in basal cell carcinoma
27 Figure 11: Top 10 companies for clinical trials in basal cell carcinoma
27 Figure 12: Trial locations in basal cell carcinoma
28 Figure 13: Basal cell carcinoma trials status
29 Figure 14: Basal cell carcinoma trials sponsors, by phase
LIST OF TABLES
13 Table 1: Marketed drugs for basal cell carcinoma
16 Table 2: Pipeline drugs for basal cell carcinoma in the US
19 Table 3: SRT-100 for Basal Cell Carcinoma (April 23, 2019)
20 Table 4: Erivedge for Basal Cell Carcinoma (March 25, 2019)
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email firstname.lastname@example.org for further help or assistance.